Barbara Barduchi Oliveira da Silva

Barbara Barduchi Oliveira da Silva

Auto-generated profile, based on publicly available information

Barbara Barduchi Oliveira da Silva

Hospital Israelita Albert Einstein, São Paulo 05652-900, SP, Brazil

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2022 in Einstein (São Paulo)
Verified
Journal Article
Open access
PDF file
BSBarbara Barduchi Oliveira da Silva
Barbara Barduchi Oliveira da Silva
MSMoacyr Silva
Moacyr Silva
FMFernando Gatti de Menezes
Fernando Gatti de Menezes
ETEduardo Juan Troster
Eduardo Juan Troster
Objective To investigate the prevalence of factors related to healthcare-associated infections, caused by multidrug-resistant bacteria, in a pediatric intensive care unit. Methods A retrospective case-control study conducted from January 1, 2007 to December 31, 2018, in São Paulo (SP), Brazil. The study was carried out at the pediatric intensive care unit of a high-complexity, tertiary care general hospital. The study included patients aged 1 month to 19 years, admitted to the pediatric intensive care unit, diagnosed as healthcare-associated infections.

1 January 2022 in American Journal of Infection Control
Verified
Journal Article
Closed access
BSBarbara Barduchi Oliveira da Silva
Barbara Barduchi Oliveira da Silva
FMFernando Gatti de Menezes
Fernando Gatti de Menezes
MSMoacyr Silva
Moacyr Silva
ETEduardo Juan Troster
Eduardo Juan Troster

6 December 2023 in Current Treatment Options in Infectious Diseases
Verified
Journal Article
Closed access
PDF file
BSBarbara Barduchi Oliveira da Silva
Barbara Barduchi Oliveira da Silva
ACAlessandra Gomes Chauvin
Alessandra Gomes Chauvin
LSLeandro Martins dos Santos
Leandro Martins dos Santos
GGGabrielli Pare Guglielmi
Gabrielli Pare Guglielmi
SASilvana Maria de Almeida
Silvana Maria de Almeida

5 November 2025 in Pathogens
Verified
Journal Article
Open access
PDF file
ACAlessandra Gomes Chauvin
Alessandra Gomes Chauvin
IPIsabele Pardo
Isabele Pardo
ACAndre Cotia
Andre Cotia
IRIsabella L. Rosmino
Isabella L. Rosmino
TMTatiana A. Marins
Tatiana A. Marins
Alexandre MarraAlexandre Marra
Alexandre Marra
Background: The COVID-19 pandemic had major global repercussions for hospitalized patients, affecting multiple aspects of hospital care. Understanding these effects is important for improving healthcare management and infection control practices. This study aimed to analyze and compare the pandemic’s impact on antimicrobial use in hospitalized patients, with emphasis on therapeutic, microbiological, and pharmacoeconomic aspects. Methods: A retrospective observational study was conducted at a Brazilian tertiary hospital (2018–2022). Adult patients receiving antimicrobials were included. Variables analyzed were antimicrobial consumption, incidence of healthcare-associated infections, resistance profiles, hospital costs, adverse drug reactions, and pharmacy activities. Data were obtained from anonymized institutional records and analyzed using descriptive statistics, time series, and linear regression. Results: Analysis of 268,713 hospitalizations showed that the median monthly number of patients receiving antimicrobials did not increase significantly during the pandemic. Higher consumption of carbapenems, glycopeptides, polymyxins, and echinocandins was linked to more healthcare-associated infections by multidrug-resistant organisms. Clostridioides difficile infections declined. Mortality rose significantly, especially among COVID-19 patients. Costs increased by 39%, with antimicrobial-related expenses up 45.7%. Conclusions: The pandemic intensified antimicrobial use, resistance, and costs. While limited by its single-center design and the use of all inpatients as the denominator, these findings highlight the important need for reinforced antimicrobial stewardship to build healthcare system resilience.

8 October 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
ACAlessandra Gomes Chauvin
Alessandra Gomes Chauvin
IPIsabele Pardo
Isabele Pardo
ACAndre Cotia
Andre Cotia
IRIsabella L. Rosmino
Isabella L. Rosmino
TMTatiana A. Marins
Tatiana A. Marins
Alexandre MarraAlexandre Marra
Alexandre Marra
Background: The COVID-19 pandemic had major global repercussions for hospitalized patients, affecting multiple aspects of hospital care. Understanding these effects is important for improving healthcare management and infection control practices. This study aimed to analyze and compare the pandemic’s impact on antimicrobial use in hospitalized patients, with emphasis on therapeutic, microbiological, and pharmacoeconomic aspects. Methods: A retrospective observational study was conducted at a Brazilian tertiary hospital (2018–2022). Adult patients receiving antimicrobials were included. Variables analyzed were antimicrobial consumption, incidence of healthcare-associated infections, resistance profiles, hospital costs, adverse drug reactions, and pharmacy activities. Data were obtained from anonymized institutional records and analyzed using descriptive statistics, time series, and linear regression. Results: Among 268,713 hospitalizations, raw counts of hospitalizations and antimicrobial use were higher during the pandemic, though monthly averages showed no significant increase. Higher consumption of carbapenems, glycopeptides, polymyxins, and echinocandins was linked to more healthcare-associated infections by multidrug-resistant organisms. Clostridioides difficile infections declined. Mortality rose significantly, especially among COVID-19 patients. Costs increased by 39%, with antimicrobial-related expenses up 45.7%. Conclusions: The pandemic intensified antimicrobial use, resistance, and costs. Strengthening antimicrobial stewardship and infection control is essential to reduce future risks.